Frequently Asked Questions
Browse our commonly asked investor-related questions
Adaptimmune is a leader in TCR T-cell therapy, focused on designing and delivering novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer. We believe our therapies have the potential to significantly impact cancer treatment and the clinical outcomes for people with cancer.
We have developed a proprietary T-cell receptor (TCR) platform that enables us to identify cancer targets, as well as genetically engineer TCRs to recognize and attack these cancer targets. We engineer a patient’s own T-cells to express these affinity-enhanced TCRs, to produce TCR T-cell treatments that we call SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell therapies. We plan to submit our first Biologics License Application (BLA) by the end of 2022 for afamitresgene autoleucel (“afami-cel”; formerly ADP-A2M4) for the treatment of people with synovial sarcoma.
Our translational science team evaluates our manufactured products, as well as pateints’ tumor and blood samples collected both before and after SPEAR T-cell therapy. This enables us to monitor how our SPEAR T-cells perform and persist in patients, and to examine how these data relate to clinical responses. Data from our translational research has led to the development of multiple next-generation approaches. Our first next-generation cell therapy targeting MAGE-A4, ADP-A2M4CD8, is currently being evaluated in the SURPASS family of trials.
Further, we have a deep preclinical pipeline with multiple autologous and allogeneic cell therapy approaches, including new next-generation SPEAR T-cells, additional TCR targets, broader HLA coverage, HLA Independent TCR (HiTs) cell therapies that eliminate the need for HLA; and next-generation Tumor Infiltrating Lymphocyte (TIL) therapies.
Cell therapy demands specific internal capabilities. Adaptimmune has been built as an integrated cell therapy company, from the ground up, with the sole purpose of designing and delivering cell therapies for people with cancer.
Pharmaceutical Preparations (2834)
Responses in six solid tumor indications demonstrate SPEAR T-cell potential to treat cancer.
The Company aims to submit a BLA for afami-cel for synovial sarcoma in 2022.
Number of autologous product batches manufactured in-house at our Navy Yard facility (Philadelphia, PA) across multiple products and tumor types.
As of March 16 2022